REVICHLO Trademark

Trademark Overview

On Wednesday, January 24, 2018, a trademark application was filed for REVICHLO with the United States Patent and Trademark Office. The USPTO has given the REVICHLO trademark a serial number of 87767954. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, August 2, 2021. This trademark is owned by Pfizer Inc.. The REVICHLO trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the treatment of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, immunological, infectious, inflammatory, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular, ophthalmological, psychiatric, respiratory, urogenital, urological and viral diseases and disorders; pharmaceutical preparations for the treatment of blood disorders, liver disorders, erectile dysfunction, sexual dysfunction, cancer, pain and diabetes; pharmaceutical preparations, namely, antifungal preparations, dermatological preparations and smoking cessation preparations; vaccines for human use
revichlo

General Information

Serial Number87767954
Word MarkREVICHLO
Filing DateWednesday, January 24, 2018
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, August 2, 2021
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, May 1, 2018

Trademark Statements

Goods and ServicesPharmaceutical preparations for the treatment of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, immunological, infectious, inflammatory, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular, ophthalmological, psychiatric, respiratory, urogenital, urological and viral diseases and disorders; pharmaceutical preparations for the treatment of blood disorders, liver disorders, erectile dysfunction, sexual dysfunction, cancer, pain and diabetes; pharmaceutical preparations, namely, antifungal preparations, dermatological preparations and smoking cessation preparations; vaccines for human use

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateSaturday, February 3, 2018
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NamePfizer Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressNew York, NY 10017
Party NamePfizer Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressNew York, NY 10017

Trademark Events

Event DateEvent Description
Monday, August 2, 2021ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, August 2, 2021ABANDONMENT - NO USE STATEMENT FILED
Friday, December 4, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, December 3, 2020EXTENSION 5 GRANTED
Thursday, November 19, 2020EXTENSION 5 FILED
Thursday, December 3, 2020CASE ASSIGNED TO INTENT TO USE PARALEGAL
Thursday, November 19, 2020TEAS EXTENSION RECEIVED
Thursday, June 11, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, June 9, 2020EXTENSION 4 GRANTED
Tuesday, June 9, 2020EXTENSION 4 FILED
Tuesday, June 9, 2020TEAS EXTENSION RECEIVED
Thursday, December 19, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, December 17, 2019EXTENSION 3 GRANTED
Tuesday, December 17, 2019EXTENSION 3 FILED
Tuesday, December 17, 2019TEAS EXTENSION RECEIVED
Tuesday, December 17, 2019CHANGES/CORRECTIONS AFTER PUB APPROVAL ENTERED
Monday, December 16, 2019ASSIGNED TO LIE
Tuesday, December 10, 2019TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Saturday, May 18, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, May 16, 2019EXTENSION 2 GRANTED
Thursday, May 16, 2019EXTENSION 2 FILED
Thursday, May 16, 2019TEAS EXTENSION RECEIVED
Friday, December 7, 2018NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, December 5, 2018EXTENSION 1 GRANTED
Wednesday, December 5, 2018EXTENSION 1 FILED
Wednesday, December 5, 2018TEAS EXTENSION RECEIVED
Tuesday, June 26, 2018NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, May 1, 2018OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, May 1, 2018PUBLISHED FOR OPPOSITION
Wednesday, April 11, 2018NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, March 27, 2018APPROVED FOR PUB - PRINCIPAL REGISTER
Monday, March 26, 2018ASSIGNED TO EXAMINER
Saturday, February 3, 2018NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Saturday, January 27, 2018NEW APPLICATION ENTERED IN TRAM

Related Keywords

revichlo preparations disorders pharmaceutical dysfunction treatment liver erectile blood viral urological